Price movement over the last 24 hours
Acadia Healthcare Company Inc vs Johnson & Johnson — how do they compare? Acadia Healthcare Company Inc trades at $30.78 (market cap $2.94B), while Johnson & Johnson trades at $266.43 (market cap $643.30B). The key difference: Johnson & Johnson is far larger — about 218.8× Acadia Healthcare Company Inc's market cap, and Johnson & Johnson pays a 2.01% dividend while Acadia Healthcare Company Inc pays none. Which is the better fit depends on your goals.
| ACHC | JNJ | |
|---|---|---|
Market Cap | $2.94B | $643.30B |
Sector | Health | Health |
52-Week High | $31.92 | $267.24 |
52-Week Low | $11.68 | $155.17 |
Enterprise Value | $5.45B | $676.24B |
Volume | — | 6,156,228 |
Dividend Yield | — | 2.01% |
Signals from Pluang's Aura AI — not financial advice
ACHC trades at $31.09, down 2.57% today but maintains a bullish technical outlook with strong moving average support. The company shows operational strength with three consecutive earnings beats, though profitability remains challenged with a -32.84% net margin. Analyst consensus is strongly bullish with 68% buy ratings, while recent news highlights the company's strategic shift toward profitability and rising behavioral health demand.
The stock presents a mixed opportunity with strong technical momentum and analyst support offset by persistent profitability challenges. Key catalysts include continued earnings outperformance and successful execution of the turnaround strategy, while risks center on margin pressures and high short interest that could limit upside potential.
Johnson & Johnson (JNJ) trades at $267.24, up 1.6% today, near its 52-week high. The stock shows strong profitability with a 21.83% net income margin and 26.42% ROE, though valuation ratios like P/E of 30.05 are elevated. Recent earnings have mostly beaten expectations, with Q1 2026 EPS of $2.70 surpassing estimates. Technical indicators are bullish, with the price above key moving averages and support at $256.
JNJ's outlook is supported by steady revenue growth and a robust dividend, but high valuation and debt-to-asset ratio of 24.06% pose risks. Analyst consensus is bullish with a $260 price target, though near-term performance may hinge on Q2 2026 earnings due July 15. Investors should weigh solid fundamentals against premium pricing and macroeconomic pressures.
Trailing returns across standard periods
Latest headlines on both assets
Acadia Healthcare is a leading provider of behavioral healthcare services across the US and Puerto Rico. It operates a network of psychiatric hospitals, residential treatment centers, and clinics for mental health and addiction recovery.
Read more on ACHC →Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →